Free Trial
NASDAQ:VRDN

Viridian Therapeutics (VRDN) Stock Price, News & Analysis

Viridian Therapeutics logo
$17.21 +1.16 (+7.25%)
As of 12:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Viridian Therapeutics Stock (NASDAQ:VRDN)

Key Stats

Today's Range
$16.12
$17.16
50-Day Range
$12.03
$16.09
52-Week Range
$9.90
$27.20
Volume
283,271 shs
Average Volume
1.15 million shs
Market Capitalization
$1.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.56
Consensus Rating
Moderate Buy

Company Overview

Viridian Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

VRDN MarketRank™: 

Viridian Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 699th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Viridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Viridian Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Viridian Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Viridian Therapeutics are expected to decrease in the coming year, from ($4.03) to ($4.31) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Viridian Therapeutics is -4.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Viridian Therapeutics is -4.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Viridian Therapeutics has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Viridian Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    14.12% of the float of Viridian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Viridian Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Viridian Therapeutics has recently increased by 5.98%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Viridian Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Viridian Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.12% of the float of Viridian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Viridian Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Viridian Therapeutics has recently increased by 5.98%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Viridian Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Viridian Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for VRDN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive VRDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VRDN Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Viridian Therapeutics: The Song Remains The Same
See More Headlines

VRDN Stock Analysis - Frequently Asked Questions

Viridian Therapeutics' stock was trading at $19.17 at the beginning of 2025. Since then, VRDN shares have decreased by 13.8% and is now trading at $16.5290.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) posted its earnings results on Tuesday, May, 6th. The company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.08. The business's quarterly revenue was up .0% compared to the same quarter last year.

Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Viridian Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/06/2025
Today
7/09/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Healthcare
Current Symbol
NASDAQ:VRDN
CIK
1590750
Employees
50
Year Founded
N/A

Price Target and Rating

High Price Target
$61.00
Low Price Target
$27.00
Potential Upside/Downside
+131.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$269.95 million
Net Margins
-102,092.39%
Pretax Margin
-102,092.39%

Debt

Sales & Book Value

Annual Sales
$300 thousand
Price / Cash Flow
N/A
Book Value
$6.09 per share
Price / Book
2.67

Miscellaneous

Free Float
81,062,000
Market Cap
$1.32 billion
Optionable
Optionable
Beta
0.39
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:VRDN) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners